Status:
COMPLETED
Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole
Lead Sponsor:
Allergan
Collaborating Sponsors:
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Conditions:
Healthy
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
Compare the DHE pharmacokinetic profiles observed following administration of: 1. MAP0004 (oral inhalation DHE) 2. MAP0004 co-administered with oral Ketoconazole 3. Intravenous (IV) DHE (D.H.E.45®, t...
Eligibility Criteria
Inclusion
- Major
- Able to provide written Informed Consent
- Male or Female subjects 18 to 45 years old
- Female subjects who are practicing adequate contraception or who are sterile
- Stable cardiac status
- Normal rhythm or arrhythmia deemed clinically insignificant on ECG
Exclusion
- Contraindication to dihydroergotamine mesylate (DHE)
- Use of any excluded concomitant medications within the 10 days prior to Visit 1
- History of hemiplegic or basilar migraine
- Participation in another investigational trial during the 12 weeks prior to Visit 1 or during this trial
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01468558
Start Date
July 1 2010
End Date
August 1 2010
Last Update
January 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Simbec Research Limited
Merthyr Tydfil, Merthyr Tydfil, United Kingdom